## UNIVERSITY OF MICHIGAN CLINICAL DRUG PIPELINE

INNOVATION PARTNERSHIPS UNIVERSITY OF MICHIGAN

| Product              | Company                   | Indication                  | Pre-Clinical | Phase I | Phase II | Phase III* | Marketed |
|----------------------|---------------------------|-----------------------------|--------------|---------|----------|------------|----------|
| Amevive              | Astellas                  | chronic plaque<br>psoriasis |              |         |          |            | 2003     |
| BEXXAR               | GSK                       | non-hodgkin's<br>lymphoma   |              |         |          |            | 2003     |
| FluMist Quadrivalent | AstraZeneca               | influenza vaccine           |              |         | _        |            | 2003     |
| Orencia              | Bristol Meyers Squibb     | rheumatoid arthritis        |              |         |          |            | 2005     |
| Cerdelga eliglustat  | Sanofi                    | Gaucher's disease           |              |         |          |            | 2014     |
| Auryxia              | Akebia                    | chronic kidney<br>disease   |              |         |          |            | 2014     |
| Kymriah              | Novartis                  | leukemia, lymphoma          |              |         |          |            | 2017     |
| Livtencity           | Takeda<br>Pharmaceuticals | CMV                         |              |         |          |            | 2021     |
| TAK-755              | Takeda<br>Pharmaceuticals | CTTP                        |              |         |          |            | 2023     |
| Xevinapant           | Merck KGaA                | cancer                      |              |         |          |            |          |
| Reparixin            | Dompe Farmaceutici        | breast cancer               |              |         |          |            |          |
| Lisaftoclax          | Ascentage Pharma          | cancer                      |              |         |          |            |          |
| Ziftomenib           | Kura Oncology             | leukemia                    |              |         |          |            |          |
| CLR 131              | Cellectar Biosciences     | leukemia, lymphoma          |              |         | -        |            |          |
| Alrizomadlin         | Ascentage Pharma          | cancer                      |              |         |          |            |          |
| Pelcitoclax          | Ascentage Pharma          | cancer & fibrosis           |              |         | -        |            |          |
| APG-1387             | Ascentage Pharma          | hepatitis B                 |              |         | -        |            |          |
| ONL 1204             | ONL Therapeutics          | retinal, glaucoma           |              |         |          |            |          |
| TNX-1300             | Tonix<br>Pharmaceuticals  | cocaine intoxication        |              |         |          |            |          |
| ESK981               | Esanik Therapeutics       | prostate cancer             |              |         | _        |            |          |

| Product                             | Company                    | Indication                         | Pre-Clinical | Phase I | Phase II | Phase III* | Marketed |
|-------------------------------------|----------------------------|------------------------------------|--------------|---------|----------|------------|----------|
| OpSCF antibody                      | Opsidio, LLC               | fibrosis                           |              |         |          |            |          |
| ZYBK2                               | Zydus Lifesciences         | rheumatoid arthritis               |              | -       |          |            |          |
| APG-2449                            | Ascentage Pharma           | cancer                             |              | -       |          |            |          |
| DT-678                              | Diapin Therapeutics        | heart attack, stroke               |              | -       |          |            |          |
| Orally-available PAI-1<br>inhibitor | MDI Therapeuitcs           | fibrosis                           |              |         |          |            |          |
| PTM-001                             | PTM Therapeutics           | ulcerative colitis                 |              |         |          |            |          |
| PTM-001-ADC                         | PTM Therapeutics           | colon cancers, solid<br>tumors     |              |         |          |            |          |
| ARD-1671                            | Proteovant<br>Therapeutics | cancer                             |              |         |          |            |          |
| SD-436                              | Proteovant<br>Therapeutics | cancer                             |              |         |          |            |          |
| NNMT inhibitors                     | Astrazeneca                | obesity, diabetes                  |              |         |          |            |          |
| MTX-531                             | MEKanistic<br>Therapeutics | cancer                             |              |         |          |            |          |
| MTX-241F                            | MEKanistic<br>Therapeutics | cancer                             |              |         |          |            |          |
| miCAS-9                             | Genetobe, LLC              | Usher syndrome,<br>cystic fibrosis |              |         |          |            |          |
| DPI-503                             | Dvant Pharma, Inc.         | cancer                             |              |         |          |            |          |
| ARBM-101                            | Arbormed Co. Ltd.          | Wilson disease                     |              |         |          |            |          |
| NanoDisc                            | EVOQ Therapeutics          | celiac disease                     |              |         |          |            |          |
| NanoDisc                            | Gilead (from EVOQ)         | rheumatoid arthritis,<br>lupus     |              |         |          |            |          |
| NanoDisc                            | Amgen (from EVOQ)          | autoimmune<br>disorders            |              |         |          |            |          |
| RT-10185                            | Resonant<br>Therapeutics   | breast, liver cancer               |              |         |          |            |          |
| DT-109                              | Diapin                     | liver disease                      |              |         |          |            |          |

## U-M CLINICAL DRUG PIPELINE //

| Product            | Company                     | Indication                      | Pre-Clinical | Phase I | Phase II | Phase III* | Markete |
|--------------------|-----------------------------|---------------------------------|--------------|---------|----------|------------|---------|
| LP-182             | Lympharma                   | cancer                          |              |         |          |            |         |
| CS-585             | Cereno Scientific           | cardiovascular                  |              |         |          |            |         |
| TBD                | STEALTH                     | retinal degeneration            |              |         |          |            |         |
| TBD                | Abcon Therapeutics,<br>Inc. | mantle cell<br>lymphoma         |              |         |          |            |         |
| TBD                | Esperovax, Inc.             | VLP vaccines                    |              |         |          |            |         |
| TBD                | KOR Life Sciences,<br>LLC   | cancer                          |              |         |          |            |         |
| TBD                | Molecure                    | fibrosis                        |              |         |          |            |         |
| TBD                | TenSixteen Bio              | age-related diseases            |              |         |          |            |         |
| TBD                | STEALTH                     | cataracts                       |              |         |          |            |         |
| TBD                | Kinesid Therapeutics        | anemia                          |              |         |          |            |         |
| nti-CitH3 Antibody | STEALTH                     | immune, cancer,<br>inf. disease |              |         |          |            |         |
| TBD                | STEALTH                     | cancer                          |              |         |          |            |         |

\*or other "registration directed" trial. "Registration directed" refers to a clinical trial which determines whether a pharmaceuitcal is safe for human use, regardless of official denomination as a Phase III trial.